BioGraphene Signs Collaborative Research Agreement with Seoul National University for the Efficacy Study of Graphene Quantum Dots in Glomerulonephritis

2019
Written By BioGraphene
 

BioGraphene Inc. announced that the company and Seoul National University entered into a Collaborative Research Agreement for the efficacy study of Graphene Quantum Dots (GQDs) in Glomerulonephritis.

Dr. Seunghee Yang, a Research Professor at Kidney Research Institute at Seoul National University Hospital will lead the research and validate GQD’s efficacy in Glomerulonephritis using in vitro/in vivo model.

Glomerulonephritis is a disease that causes damage to the kidneys and interferes with their ability to remove waste, which can lead to other complications such as high blood pressure or kidney failure.

BioGraphene
Previous

BioGraphene Signs Collaboration Agreement with NICHD to Initiate Efficacy Studies of Graphene Quantum Dots in Lysosomal Storage Disorders Using Animal Models
Next

BioGraphene Announces Publication in Nature Nanotechnology on Graphene Quantum Dots’ Ability to Ameliorate Pathology and Behavioral Deficits in Parkinson’s Disease